| July 31, 2023 |
Timely Disclosure Information
|
StemRIM Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Japan)
|
| July 25, 2023 |
Timely Disclosure Information
|
StemRIM Announces the Initiation of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Europe, China)
|
| July 18, 2023 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (Korea) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
|
| May 24, 2023 |
Timely Disclosure Information
|
StemRIM Announces Orphan Drug Designation of Regeneration-Inducing Medicine Redasemtide (HMGB1 peptide)
|
| May 22, 2023 |
Timely Disclosure Information
|
StemRIM Announces Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease (Additional Report)
|
| May 18, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Patent Registration (Taiwan) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
|
| April 28, 2023 |
Timely Disclosure Information
|
StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke
|
| April 11, 2023 |
Timely Disclosure Information
|
[Delayed] StemRIM Announces Preliminary Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease
|
| April 11, 2023 |
Timely Disclosure Information
|
[Delayed] Notice of Earnings Forecasts for the Fiscal Year Ending July 31, 2023
|
| April 11, 2023 |
Timely Disclosure Information
|
[Delayed] StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke
|
